Search Results

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech.

Alveo Technologies, Inc., a leader in molecular sensing and diagnostics with its proprietary technology platform, announced the results of rigorous testing that demonstrate the ruggedness of its portable molecular testing platform.

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights.

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG) today announced the pricing of a public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants.

The molecular diagnostics market size reached a value of $15.42 billion in 2023 and is expected to rise to $25.27 billion by 2032, growing at a CAGR of 5.3% for the forecast period from 2024 to 2032.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, reported financial results for the quarter ended September 30, 2022 and provided recent business highlights.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader webinar: “The Role of RNA Profiling in Drug Discovery and Analysis,” hosted on Tuesday, December 13, 2022.

The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.